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Objectives: Raynaud’s phenomenon (RP) is characterized by intense vasospasm of the
digital arteries that causes characteristic color changes in fingers. There are two main
types of RP: Primary RP (PRP) and Secondary RP (SRP). PRP is a benign condition.
Whilst SRP is associated with several connective tissue diseases (CTD), in particular
systemic sclerosis (SSc). The objectives of this report were: to present a short review
on morphological (nailfold videocapillaroscopy, NVC) and functional techniques (laser
tools and thermography) that allow for a correct diagnosis and treatment of RP and to
investigate blood perfusion (BP) by laser speckle contrast analysis (LASCA) in different
skin areas of hands and face in PRP, SRP to SSc, and healthy subjects (CNT).
Methods: 31 PRP patients (LeRoy criteria), 70 SRP to SSc (ACR/EULAR criteria) and
68 CNT were enrolled. BP was assessed by LASCA at the level different areas of hands
and face. NVC was performed to distinguish between PRP and SRP, and to detect the
proper pattern of nailfold microangiopathy in SSc patients.
Results: Both PRP and SRP showed a statistically significant lower BP than CNT at
the level of fingertips (p < 0.0001), periungual (p < 0.0001), palmar aspect of 3rd finger
(p < 0.0001), and palm areas (p < 0.0001). Moreover, BP was significantly lower in PRP
than in SRP to SSc with the “Early” pattern of microangiopathy in the same areas as
above (p < 0.04).
Conclusion: By considering a small cohort of patients, BP of hands was found lower
in PRP than in SSc patients with the “Early” NVC pattern of microangiopathy.
Keywords: Raynaud’s phenomenon, systemic sclerosis, microvascular damage, nailfold videocapillaroscopy,
peripheral blood perfusion, laser techniques
SHORT REVIEW AND INTRODUCTION
Raynaud’s phenomenon (RP), first described in 1862 by Maurice Raynaud (Fardoun
et al., 2016; Wigley and Flavahan, 2016), is present in 5–10% of the world’s population.
It is a clinical consequence of recurrent vasospasm of the small arteries and arterioles
of the fingers and toes triggered by cold or even emotional stress (Wigley and
Flavahan, 2016), at times also affecting the nose, ears, or lips (Block and Sequeira, 2001;
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Herrick, 2005; McMahan and Wigley, 2010; Hughes and
Herrick, 2016). The skin usually turns white (ischemia),
blue (deoxygenation) and then red (reperfusion) (Block and
Sequeira, 2001; Herrick, 2005; McMahan and Wigley, 2010;
Hughes and Herrick, 2016).
There are two main categories, i.e., Primary (PRP) and
Secondary RP (SRP) and most are PRP that have an isolated
finding if there is no underlying pathology (idiopathic). SRP
is present in various conditions, like connective tissue diseases
(CTD), such as systemic sclerosis (SSc).
Ninety percent of SSc patients have RP which is the most
common presenting feature and may precede diagnosis by
many years (Block and Sequeira, 2001; Herrick, 2005; McMahan
and Wigley, 2010; Hughes and Herrick, 2016). The suggested
criteria for PRP include symmetric attacks, the absence of tissue
necrosis, ulceration or gangrene, the absence of a secondary
cause, negative tests for antinuclear antibodies and a normal
erythrocyte sedimentation rate (LeRoy and Medsger, 1992, 2001).
When PRP diagnosis is made no underlying disease has
yet been identified, making prediction of if and when it may
turn into SRP difficult (Ingegnoli et al., 2010; Avouac et al.,
2011; Bernero et al., 2013; Cutolo et al., 2017a). Nailfold video-
capillaroscopy (NVC) is able to distinguish SRP from both PRP
and healthy subjects by detecting morphological microcirculation
abnormalities (Block and Sequeira, 2001; Cutolo et al., 2003;
Herrick, 2005; Ingegnoli et al., 2017; Pizzorni et al., 2017b;
Herrick and Murray, 2018). Follow-up nailfold capillaroscopic
analysis should be performed every 6 months in PRP patients
(Cutolo et al., 2003; Bernero et al., 2013).
Nailfold capillaries in PRP are usually normal in shape without
any specific alterations (Ingegnoli et al., 2013; Smith et al., 2016a)
or abnormal capillaroscopic findings, i.e., giant capillaries and
microhemorrhages, whilst their presence is diagnostic for the
“Early” NVC pattern of scleroderma microangiography (Cutolo
et al., 2003, 2017a; Bernero et al., 2013; Ingegnoli et al., 2013;
Smith et al., 2016a).
Indeed, abnormal nailfold capillaroscopic images (more
specifically “scleroderma patterns”) were included in the 2013
European League Against Rheumatism and American College of
Rheumatology classification criteria for SSc to this aim (van den
Hoogen et al., 2013).
Digital vasculopathy is structural and functional in SRP due to
SSc. NVC cannot measure blood perfusion (BP) under standard
conditions (Mugii et al., 2009) but other techniques, like laser
and thermography as well as emerging technologies are able
to evaluate and quantify skin blood flow and perfusion in SSc
(Wigley et al., 1990; Clark et al., 2003; Murray et al., 2009; Rosato
et al., 2009, 2011; Cutolo et al., 2010, 2014, 2018b; Pauling et al.,
2012a,b, 2015; Della Rossa et al., 2013; Ruaro et al., 2014, 2016,
2017b, 2018c; Sulli et al., 2014; Lambrecht et al., 2016; Wilkinson
et al., 2018). Laser Doppler flowmetry (LDF) evaluates blood
flow at a single skin point, providing an index of skin perfusion
(Cutolo et al., 2010, 2014; Ruaro et al., 2017b, 2018c).
Laser Doppler imaging (LDI) may also be used to evaluate
the microcirculatory blood flow (Wigley et al., 1990; Clark et al.,
2003; Murray et al., 2009; Rosato et al., 2009, 2011). LDI assesses
more than one area and is more effective than a single probe
Doppler (Wigley et al., 1990; Clark et al., 2003; Murray et al., 2009;
Rosato et al., 2009, 2011). LDI can help to differentiate between
PRP and patients with SRP to scleroderma (Wigley et al., 1990;
Clark et al., 2003; Murray et al., 2009; Rosato et al., 2009, 2011).
Although Murray et al. suggested that combining laser Doppler
with other imaging modalities (e.g., nailfold capillaroscopy and
thermal imaging) is more effective than laser Doppler alone,
these functional imaging tools are not yet widely available
(Murray et al., 2009).
Laser speckle contrast analysis (LASCA) can quantify the
blood flow over a defined area and is based on the principle that
when laser light illuminates a tissue it forms a speckle pattern
(Della Rossa et al., 2013; Ruaro et al., 2014; Lambrecht et al., 2016;
Cutolo et al., 2018b). Changes in this pattern are analyzed by
software and the static areas show a stationary speckle pattern,
in contrast with the moving objects like red blood cells that
cause the speckle pattern to fluctuate and appear blurred. The
level of blurring (contrast) is analyzed and interpreted as BP
(Cutolo et al., 2017a; Ingegnoli et al., 2017). LASCA is a fast
imaging technique, with a high resolution and reliability, as
recently demonstrated in two studies (Lambrecht et al., 2016;
Cutolo et al., 2018b).
LASCA has been applied in research studies on RP and
SSc (Della Rossa et al., 2013; Ingegnoli et al., 2013, 2017) and
one demonstrated that peripheral BP evaluated by both LDF
and LASCA correlates to the extent of the microangiopathy
(Ruaro et al., 2014).
Laser speckle contrast imaging (LCSI) is similar to LASCA and
provides a five-fold increase in spatial resolution over LASCA.
However, it is more time consuming (Pauling et al., 2015).
Thermal imaging (TI), an indirect method, makes use of
a thermal camera to image the skin temperature to show the
underlying blood flow (Clark et al., 2003; Murray et al., 2009;
Pauling et al., 2012a,b; Wilkinson et al., 2018). TI evaluated RP
in several studies and the response to lower temperatures (cold)
was able to differentiate between PRP and SRP to SSc (Murray
et al., 2009). However, it has a poor sensitivity in detecting BP
variations and has a low spatial resolution (Murray et al., 2009).
Non-invasive assessment of the morphological and functional
peripheral circulation may supplement the physical examination
and provide a quick, accurately diagnosis, ultimately guiding the
correct treatment for both PRP and SRP (Filaci et al., 1999,
2001; Faggioli et al., 2006; Pyrpasopoulou and Aslanidis, 2007;
Aschwanden et al., 2008; Caramaschi et al., 2009; Miniati et al.,
2009; Shah et al., 2011; Guiducci et al., 2012; Roustit et al., 2012;
Cutolo et al., 2013, 2017b; Herrick, 2013, 2017; Cutolo and Sulli,
2015; Gladue et al., 2016; Smith et al., 2016b; Trombetta et al.,
2016; Burmester et al., 2017; Kowal-Bielecka et al., 2017; Ruaro
et al., 2017a; Rotondo et al., 2018).
Most PRP patients have no serious symptoms and respond
well to conservative non-medical treatment like keeping warm
and avoiding drugs with vasoconstrictive effects. Whilst other
cases require pharmacological treatment like calcium channel
blockers as first-line therapy (Herrick, 2013). Although various
treatment options are available for the management of SSc-
related SRP, these approaches at most reduce the severity of the
symptoms but do not resolve the clinical situation (Herrick, 2013;
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Cutolo and Sulli, 2015; Gladue et al., 2016; Herrick, 2017;
Kowal-Bielecka et al., 2017).
The revised European League Against Rheumatism (EULAR)
recommendations for RP in SSc patients (SSc-RP) treatment
state that “calcium channel blockers should be used as first-
line therapy and PDE-5 inhibitors in patients with SSc with
severe RP and/or those who do not satisfactorily respond
to calcium channel blockers” (Kowal-Bielecka et al., 2017).
The experts recommended that “intravenous prostanoids
are considered when oral therapies (including calcium
channel blockers and PDE-5 inhibitors) have failed” and
they also recognize that “fluoxetine is a useful alternative
for treatment of SSc-RP, in particular in patients with SSc
who cannot tolerate or do not respond to vasodilators”
(Kowal-Bielecka et al., 2017).
As aforementioned, the current therapies for RP are often
ineffective. Therefore, the biggest challenge is identifying
a drug able to halt RP progression or better still, to
prevent the microvascular anomalies which involve tissue
hypoperfusion and hypoxia.
That is why an NVC-based assessment of microvascular
structure and an evaluation of functional impairment by laser
tools and thermography may be useful to assess the efficacy of
pharmacological therapies during the treatment of RP patients.
Interestingly, some studies used NVC to detect the
microvascular changes as possible markers of response to
immunosuppressive/anti-fibrosing treatment and vasoactive
drugs (Filaci et al., 1999, 2001; Faggioli et al., 2006;
Pyrpasopoulou and Aslanidis, 2007; Caramaschi et al., 2009;
Miniati et al., 2009; Shah et al., 2011; Guiducci et al., 2012;
Cutolo et al., 2013; Smith et al., 2016b; Trombetta et al., 2016;
Ruaro et al., 2017a). Early studies on the effect of Cyclosporin
have shown a moderate improvement in clinical symptoms and
SSc nailfold microangiopathy, after a 12 month treatment cycle
(Filaci et al., 2001; Caramaschi et al., 2009).
Similarly, Cyclophosphamide administration was reported to
be significantly associated with an improvement in microvascular
damage and a regression of the capillaroscopic pattern severity
(Caramaschi et al., 2009).
A recent study showed no progression (therefore a positive
disease modifying effect) of the microvascular damage (mainly
no further capillary loss) during the 12-month follow-up in
patients with early SSc and diffuse skin involvement treated with
Rituximab (Smith et al., 2016b).
Recent studies have reported that the use of autologous
haemopoietic stem cell transplantation in patients with
severe diffuse SSc improved microangiopathy and the NVC
pattern changed from “Late” to “Active” (Miniati et al.,
2009). Three studies reported an improvement in nailfold
microvascularization after iloprost treatment (Faggioli et al.,
2006; Pyrpasopoulou and Aslanidis, 2007; Shah et al., 2011;
Rotondo et al., 2018). Various studies used NVC with laser
techniques to access the drug response in SSc patients treated
with a combination of intravenous prostanoids and endothelin-
1 receptor blockers, reporting a significant capillary loss
reduction (Guiducci et al., 2012; Cutolo et al., 2013, 2014, 2016;
Trombetta et al., 2016; Ruaro et al., 2017a).
The objectives of this study were:
(i) to provide a short review in the introduction on
morphological (NVC) and functional techniques (laser
tools and thermography) that allow for a correct early
diagnosis and treatment of primary and PRP;
(ii) to present a pilot study that compares BP measured
by LASCA in different skin areas of the hands and face in
patients with PRP, SRP to SSc and healthy subjects (CNT).
PATIENTS AND METHODS OF THE
PILOT STUDY
Study Population
A total of 31 PRP patients were enrolled after having obtained
their written informed consent for the use of imaging and the
demographic data as educational material and for publications.
All the PRP patients fulfilled the LeRoy criteria (LeRoy
and Medsger, 2001) as did 68 SSc patients, who met
the ACR/EULAR 2013 criteria for SSc (van den Hoogen
et al., 2013) during routine clinical assessment in our
Rheumatology Department, from October, 2016 to Mach,
2017. The study was carried out according to the ethical
standard of Good Clinical Practice. A complete medical
history was collected and all participants had a clinical
examination (Table 1).
The inclusion criteria were a diagnosis of PRP or SRP to SSc,
and all patients had been on a stable drug regimen for at least
2 months prior study entry.
The exclusion criterion was being on a drug regimen that
could potentially influence blood flow.
If the patients were being treated with prostanoids and
endothelin-1 receptor antagonists, they were temporarily
withdrawn 1 month before instrumental assessment.
All SSc patients were taking aspirin (average dosage
100 mg/day) at the time of the study. Other concomitant
treatment included: proton pump inhibitors (used by #52
patients), antihypertensive drugs i.e., angiotensin-converting
enzyme (ACE) inhibitors (#9 patients), cyclosporine (average
dosage 150 mg/day: #12 patients), methotrexate (average dosage
7.5 mg/week: #12 patients). The PRP therapy treatment was:
proton pump inhibitors (used by #8 patients), antihypertensive
drugs i.e., ACE inhibitors (#3 patients).
Both LASCA and NVC were performed on the same day in all
PRP and SSc patients.
Laser speckle contrast analysis was also performed in the 70
healthy subjects (CNT) matched with the RP patients for age and
gender (see Table 1 for demographic data).
Laser Speckle Contrast Analysis (LASCA)
Skin BP was analyzed by the LASCA technique (Pericam
PSI, Perimed, Milan, Italy) at the level of dorsal and palmar
aspect of hands and the whole face, in both SSc patients
and healthy subjects as previously described (Ruaro et al.,
2014, 2016; Sulli et al., 2014). Different regions of interest
(ROIs) were created, as previously reported, i.e., at the level
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TABLE 1 | Clinical findings in patients with primary Raynaud’s phenomenon (PRP), systemic sclerosis (SSc) and healthy subjects (CNT).
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
CNT# 70 PRP # 31 SSc # 68 Early # 22 Active # 23 Late # 23 lcSSc # 54 dcSSc # 14
Age (years) 59 (22) 58 (24) 61 (18) 59 (20) 60 (14) 62 (13) 60 (17) 61 (14)
Gender (M/F) 4/66 1/30 3/65 1/21 1/22 1/22 3/51 1/13
Smokinghabit 3/67 2/29 3/65 2/20 1/22 0/23 2/52 1/13
RPduration (years) NA 2 (1) 10 (8) 7 (6) 8 (7) 14 (12) 12 (8) 9 (8)
SScduration (years) NA NA 7 (6) 2 (2) 4 (4) 7 (7) 6 (6) 8 (6)
The SSc study group was also classified according to the microangiopathy patterns and skin involvement (RP = Raynaud’s phenomenon; mRSS = modified Rodnan skin
score; Early, Active, Late = patterns of microangiopathy at nailfold videocapillaroscopy; lcSSc = limited cutaneous SSc; dcSSc = diffuse cutaneous SSc).
of fingertips, periungual areas, dorsal and palmar aspect of
the 3rd finger bilaterally, the dorsum and palm of both
hands and face (forehead, tip of nose, zygomas and perioral
region) (see Figure 1 for ROI areas) (Sulli et al., 2014;
Ruaro et al., 2016, 2018b).
The average BP from either fingertips or periungual areas
was calculated by summing the perfusion values of eight
fingers together and then dividing the final value by the
number of fingers.
The average BP from the two palmar and dorsal areas
of the fingers, palm and dorsum of the hands and zygoma
was calculated by summing the perfusion values of the
two sides (right and left) and then dividing the final value
by two. The BP was quantified as perfusion units (PU;
Sulli et al., 2014; Ruaro et al., 2016). The same operator
(BR) performed the examination in all PRP, SRP-SSc
patients and CNT.
Nailfold Videocapillaroscopy (NVC)
All patients were assessed by nailfold videocapillaroscopy (NVC),
(equipped with a 200× contact lens, connected to image analysis
software – Videocap, DS MediGroup, Milan, Italy) so as to
distinguish PRP from SRP and to determine the correct nailfold
microangiopathy pattern (“Early,” “Active,” or “Late” pattern,
according to the Cutolo’s criteria) in the SSc patients (Sulli
et al., 2008; Smith et al., 2010, 2013; Table 1). The same
operator (CP) performed the examination in all PRP and SRP-SSc
patients and CNT.
Statistical Analysis
The statistical analysis was carried out by parametric procedures
and confirmed by non-parametric tests. The Mann-Whitney U
test was performed to compare unpaired groups of variables,
along with the Kruskal-Wallis test to compare continuous
variables with nominal variables that had more than two levels.
FIGURE 1 | Laser Speckle Contrast Analysis (LASCA) images of secondary Raynaud’s phenomenon (RP) to systemic sclerosis, in a patient with a “Late” pattern of
scleroderma microangiopathy (A), primary RP (B) and a healthy subject (C), showing the regions of interest (ROI - white circles) created at the level of dorsum and
palm of the hand, dorsal and palmar aspect of the 3rd finger, periungual areas and fingertips to evaluate blood perfusion. Color code: blue corresponds to a low BP,
yellow an intermediate BP and red a higher BP. Noteworthy is the fact that subjects with a late pattern have a prevalence of blue, indicating a low perfusion level.
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Any p-values below 0.05 were considered statistically significant.
The results are given as, median and interquartile range (IQR).
RESULTS
Both PRP and SSc patients had statistically significant lower
BP than the healthy subjects at the fingertip (p < 0.0001), the
periungual area (p < 0.0001), the palmar aspect of the 3rd finger
(p < 0.0001) and the palm areas (p < 0.0001). Conversely, all
three groups had similar BP values in the other areas of the hand
(dorsal aspect of the 3rd finger and dorsum of hand) and face
(forehead, tip of nose, zygomas and perioral region). Moreover,
BP was statistically significantly lower in PRP than in SSc
patients with the “Early” pattern of microangiopathy at fingertip
(p = 0.04), periungual (p < 0.05), palmar aspect of the 3rd finger
(p = 0.0008) and the palm areas (p = 0.0009). No statistically
significant difference was observed between PRP and the “Early”
pattern of microangiopathy in the other areas evaluated.
A statistically significant progressive decrease in BP was
confirmed in SSc patients with a progressive pattern of nailfold
microangiopathy (“Early,” “Active,” and “Late”) at the fingertip,
periungual, palmar aspect of the 3rd fingers and palm areas
(p < 0.05). No statistically significant difference was observed
between NVC patterns and BP at the level of the other areas
(dorsum of hands, whole face and different areas of face)
(p> 0.05) (Table 2).
If the three nailfold microangiopathy patterns (“Early,”
“Active,” and “Late”) are evaluated separately, there is a
statistically significant difference only between the “Early” and
“Late” group, at the level of the fingertip, periungual, palmar
aspect of the 3rd fingers and palm areas (p< 0.05). No statistically
significant difference was observed in the other areas.
There were very few smokers in our study and there
was no statistically significant difference in the smoking habit
between the groups.
DISCUSSION
Our pilot study shows that the hand BP, evaluated by LASCA,
was lower in PRP than in SSc patients with an “Early” NVC
microangiopathy pattern.
The results of this study also confirm that SSc patients
had a significant lower median BP than healthy subjects and
the progressive decrease of BP in SSc patients with different:
“Early,” “Active,” or “Late” NVC pattern of microangiopathy at
the level of hand.
Indeed, some authors have reported different perfusion values
in PRP and SRP to SSc patients, but the perfusion was evaluated
either after, or during, different forms of stress, such as the cold
or occlusion test, in contrast with our study where the perfusion
was evaluated at basal condition (Pauling et al., 2012a, 2015).
We would like to attest that all the PRP patients had a
functional disorder/dysfunction in microvascular circulation and
our data emphasize the importance of the perfusion reduction,
even in a functional phenomenon such as in PRP patients.
Moreover, our data are in agreement with those of other
studies that report NVC as being the best method to evaluate
TABLE 2 | Blood perfusion (BP) in systemic sclerosis (SSc), primary Raynaud’s phenomenon (PRP) and healthy subjects (CNT).
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)
Statistical significance
CNT #
70
PRP #
31
SSc #
68
Early #
22
Active
# 23
Late #
22
CNT vs.
PRP
CNT vs.
SSc
PRP vs.
SSc
E vs. A E vs. L A vs L
BP fingertips 187 (72) 90 (28) 88 (25) 92 (58) 88 (19) 82 (40) p < 0.0001 p < 0.0001 p = 0.6 p = 0.2 p = 0.006 p = 0.1
BP palmar aspect
of the 3rd phalanx
134 (74) 84 (19) 81 (27) 88 (25) 80 (20) 72 (35) p < 0.0001 p < 0.0001 p = 0.4 p = 0.06 p = 0.007 p = 0.2
BP palm of hands 114 (27) 81 (22) 79 (31) 85 (22) 83 (31) 68 (39) p < 0.0001 p < 0.0001 p = 0.05 p = 0.4 p = 0.01 p = 0.04
BP periungual
areas
143 (51) 78 (28) 76 (38) 82 (34) 76 (47) 68 (42) p < 0.0001 p < 0.0001 p = 0.7 p = 0.1 p = 0.02 p = 0.3
BP dorsal aspect of
the 3rd phalanx
55 (28) 59 (16) 58 (24) 61 (19) 59 (25) 57 (24) p = 0.5 p = 0.09 p = 0.8 p = 0.2 p = 0.3 p = 0.6
BP dorsum of
hands
51 (27) 50 (13) 52 (18) 56 (22) 50 (19) 49 (16) p = 0.4 p = 0.07 p = 0.9 p = 0.1 p = 0.1 p = 0.8
BP forehead 109 (44) 113 (32) 110 (33) 112 (21) 110 (29) 111 (31) p = 0.1 p = 0.09 p = 0.3 p = 0.2 p = 0.3 p = 0.8
BP tip of nose 129 (45) 139 (42) 130 (42) 132 (42) 129 (36) 130 (56) p = 0.2 p = 0.09 p = 0.3 p = 0.5 p = 0.09 p = 0.3
BP zygoma 127 (48) 155 (45) 145 (58) 150 (45) 145 (55) 143 (83) p = 0.4 p = 0.1 p = 0.2 p = 0.3 p = 0.2 p = 0.1
BP perioral region 144 (48) 141 (39) 135 (46) 134 (45) 136 (46) 134 (56) p = 0.1 p = 0.1 p = 0.3 p = 0.2 p = 0.1 p = 0.3
BP whole face 135 (34) 146 (28) 136 (42) 140 (32) 131 (36) 130 (68) p = 0.2 p = 0.3 p = 0.1 p = 0.2 p = 0.1 p = 0.2
SSc patients with different capillaroscopic patterns of nailfold microangiopathy (Early, Active, Late), evaluated by LASCA in different areas of the hands (fingertips,
periungual areas, dorsal and palmar aspect of the 3rd phalanx bilaterally, dorsum and palms of both hands) and face (forehead, tip of nose, zygomas and perioral region).
Statistical significance: Mann-Witney U-test (# = numbers, E = Early, A = Active, L = Late). The statistical significance columns show the blood perfusion difference
between the CNT (healthy subjects) and the PRP (primary Raynaud’s phenomenon) and the systemic sclerosis (SSc) patients. The three capillaroscopic patterns of
nailfold microangiopathy (Early, Active, Late), evaluated by LASCA, are also documented.
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microcirculation morphological and permanent damage and to
make a differential diagnosis between PRP and SRP (Murray
et al., 2009; Ingegnoli et al., 2017; Herrick and Murray, 2018).
As previously reported our data confirm that patients with the
“Late” SSc microangiopathy pattern had a lower blood flow than
those with the “Active” or “Early” SSc patterns at NVC (Ruaro
et al., 2014, 2018b). In our precedent article we also reported
that when BP was assessed by the LASCA technique significantly
lower values were observed in the SSc patients than in the healthy
subjects at the level of the fingertips, periungual areas and palm
of the hands, with a statistically significant negative correlation
between the extent of the nailfold microangiopathy and the
BP values at the level of the same skin areas in SSc patients
(Ruaro et al., 2014, 2018b).
The increased interest in microcirculation has led to a
rapid development of new assessment methods. However, these
techniques lack the support of validation studies as to their
application in clinical practice. Nevertheless, microvascular
structure evaluation by NVC combined with functional
investigation by laser techniques or TI, not only helps in the
distinction between primary and SRP, but is also able to evaluate
therapy response and disease progression (Filaci et al., 2001;
Caramaschi et al., 2009; Guiducci et al., 2012; Cutolo et al., 2013,
2014, 2016; Smith et al., 2013, 2016b; Trombetta et al., 2016;
Ruaro et al., 2017a, 2018a, Pizzorni et al., 2017a; Soulaidopoulos
et al., 2017; Markusse et al., 2017).
In particular, the assessment of the number of capillary
changes seems the best validated NVC parameter and is today
evaluable with automated systems (Cutolo et al., 2018a).
In summary we are of the opinion that morphological
evaluation by NVC is the best method for the early detection and
quantification of microvascular abnormalities that characterize
SRP. We also believe that clinicians should not underestimate
RP which should have a scheduled follow-up as it might
well be a precocious cloaked clinical sign of abnormal
microcirculation and a risk factor for the development of a
CTD, especially SSc.
Last but not least, the main message of this work is that
while today there is no curative treatment all RP patients,
because it is a very heterogeneous phenomenon, still there
are many treatment options to improve quality of life of
these patients. The early detection of disease and immediate
intervention appears to make a difference, such as well-
designed clinical trials and collaboration with networks, such
as the European Reference Network on Rare and Complex
Connective Tissue and Musculoskeletal Diseases Project and
specialized centers carrying the research in this field with
the aim of defining ideal diagnostic and therapeutic options
(Smith et al., 2018).
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